ondansetron/pyridostigmine (DAS-001) / DAS Therap - LARVOL DELTA

Study of Pyridostigmine With Ondansetron in Subjects With Anti-AchR Positive Myasthenia Gravis (clinicaltrials.gov) - P2 | N=2 | Terminated | Sponsor: DAS-MG, Inc | N=24 ➔ 2 | Trial completion date: Sep 2026 ➔ Apr 2025 | Recruiting ➔ Terminated | Trial primary completion date: Jul 2025 ➔ Apr 2025; lack of enrollment

Enrollment change • Trial completion date • Trial primary completion date • Trial termination • CNS Disorders • Myasthenia Gravis

Study of Pyridostigmine With Ondansetron in Subjects With Anti-AchR Positive Myasthenia Gravis (clinicaltrials.gov) - P2 | N=24 | Recruiting | Sponsor: DAS-MG, Inc | Trial completion date: Apr 2023 ➔ Sep 2026 | Trial primary completion date: Apr 2023 ➔ Jul 2025

Trial completion date • Trial primary completion date • CNS Disorders • Myasthenia Gravis

Study of Pyridostigmine With Ondansetron in Subjects With Anti-AchR Positive Myasthenia Gravis (clinicaltrials.gov) - P2 | N=24 | Recruiting | Sponsor: DAS-MG, Inc | Trial completion date: Apr 2022 ➔ Apr 2023 | Trial primary completion date: Apr 2022 ➔ Apr 2023

Trial completion date • Trial primary completion date • CNS Disorders • Myasthenia Gravis

Study of Pyridostigmine With Ondansetron in Subjects With Anti-AchR Positive Myasthenia Gravis (clinicaltrials.gov) - P2; N=24; Recruiting; Sponsor: DAS-MG, Inc; Not yet recruiting ➔ Recruiting

Enrollment open • CNS Disorders • Complement-mediated Rare Disorders • Myasthenia Gravis

Study of Pyridostigmine With Ondansetron in Subjects With Anti-AchR Positive Myasthenia Gravis (clinicaltrials.gov) - P2; N=24; Not yet recruiting; Sponsor: DAS-MG, Inc; Trial completion date: Apr 2021 ➔ Sep 2021; Initiation date: Apr 2020 ➔ Sep 2020; Trial primary completion date: Apr 2021 ➔ Sep 2021

Clinical • Trial completion date • Trial initiation date • Trial primary completion date • CNS Disorders • Complement-mediated Rare Disorders • Myasthenia Gravis

A Phase II Study of Pyridostigmine With Ondansetron in Subjects With Anti-AchR Positive Myasthenia Gravis (clinicaltrials.gov) - P2; N=24; Not yet recruiting; Sponsor: DAS-MG, Inc

Clinical • New P2 trial